Robert W. Baird Trims ICON Public (NASDAQ:ICLR) Target Price to $340.00

ICON Public (NASDAQ:ICLR) had its target price lowered by Robert W. Baird from $368.00 to $340.00 in a report published on Friday, Benzinga reports. The firm currently has an outperform rating on the medical research company’s stock.

Other equities analysts have also issued research reports about the stock. The Goldman Sachs Group assumed coverage on shares of ICON Public in a report on Thursday, June 6th. They issued a buy rating and a $370.00 price objective on the stock. Leerink Partners began coverage on ICON Public in a report on Wednesday, September 18th. They issued an outperform rating and a $379.00 price target for the company. StockNews.com lowered ICON Public from a buy rating to a hold rating in a research note on Thursday. Leerink Partnrs raised ICON Public to a strong-buy rating in a research report on Wednesday, September 18th. Finally, TD Cowen raised their price target on shares of ICON Public from $349.00 to $373.00 and gave the stock a buy rating in a research report on Friday, May 31st. One analyst has rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of Buy and an average target price of $351.60.

ICON Public Price Performance

ICLR stock opened at $303.07 on Friday. The firm has a market cap of $25.00 billion, a P/E ratio of 36.87, a price-to-earnings-growth ratio of 1.29 and a beta of 1.22. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.31 and a current ratio of 1.31. ICON Public has a 1 year low of $221.20 and a 1 year high of $347.72. The stock has a 50-day simple moving average of $317.00 and a 200-day simple moving average of $317.95.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.68 by $0.07. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The company had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.14 billion. During the same quarter last year, the company earned $2.96 earnings per share. ICON Public’s revenue for the quarter was up 4.1% on a year-over-year basis. On average, equities analysts predict that ICON Public will post 14.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ICON Public

Institutional investors have recently modified their holdings of the business. CIBC Private Wealth Group LLC boosted its stake in ICON Public by 0.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 695,932 shares of the medical research company’s stock valued at $196,998,000 after acquiring an additional 6,331 shares during the period. State of Tennessee Treasury Department grew its stake in ICON Public by 4.9% during the 4th quarter. State of Tennessee Treasury Department now owns 155,797 shares of the medical research company’s stock worth $44,101,000 after buying an additional 7,270 shares during the last quarter. Kornitzer Capital Management Inc. KS increased its position in ICON Public by 15.9% in the second quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company’s stock worth $30,016,000 after buying an additional 13,163 shares during the period. GAMMA Investing LLC boosted its holdings in shares of ICON Public by 50.0% during the second quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock valued at $82,000 after acquiring an additional 87 shares during the period. Finally, Riverview Trust Co acquired a new stake in shares of ICON Public in the 1st quarter worth about $31,000. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.